Individual Analysis of Molecular Brain Imaging Data Through Automatic Identification of Abnormality Patterns

International audienceWe introduce a pipeline for the individual analysis of positron emission tomography (PET) data on large cohorts of patients. This pipeline consists for each individual of generating a subject-specific model of healthy PET appearance and comparing the individual's PET image to the model via a novel regularised Z-score. The resulting voxel-wise Z-score map can be interpreted as a subject-specific abnormality map that summarises the pathology's topographical distribution in the brain. We then propose a strategy to validate the abnormality maps on several PET tracers and automatically detect the underlying pathology by using the abnormality maps as features to feed a linear support vector machine (SVM)-based classifier. We applied the pipeline to a large dataset comprising 298 subjects selected from the ADNI2 database (103 cognitively normal, 105 late MCI and 90 Alzheimer's disease subjects). The high classification accuracy obtained when using the abnormality maps as features demonstrates that the proposed pipeline is able to extract for each individual the signal characteristic of dementia from both FDG and Florbetapir PET data

Local molecular and global connectomic contributions to cross-disorder cortical abnormalities

Contains fulltext : 253170.pdf (Publisher’s version ) (Open Access

Atlas construction and image analysis using statistical cardiac models

International audienceThis paper presents a brief overview of current trends in the construction of population and multi-modal heart atlases in our group and their application to atlas-based cardiac image analysis. The technical challenges around the construction of these atlases are organized around two main axes: groupwise image registration of anatomical, motion and fiber images and construction of statistical shape models. Application-wise, this paper focuses on the extraction of atlas-based biomarkers for the detection of local shape or motion abnormalities, addressing several cardiac applications where the extracted information is used to study and grade different pathologies. The paper is concluded with a discussion about the role of statistical atlases in the integration of multiple information sources and the potential this can bring to in-silico simulations

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis

Multifactorial mechanisms underlying late-onset Alzheimer’s disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-β deposition, metabolism, vascular, functional activity at rest, structural properties, cognitive integrity and peripheral proteins levels are characterized in relation to LOAD progression. We analyse over 7,700 brain images and tens of plasma and cerebrospinal fluid biomarkers from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Through a multifactorial data-driven analysis, we obtain dynamic LOAD–abnormality indices for all biomarkers, and a tentative temporal ordering of disease progression. Imaging results suggest that intra-brain vascular dysregulation is an early pathological event during disease development. Cognitive decline is noticeable from initial LOAD stages, suggesting early memory deficit associated with the primary disease factors. High abnormality levels are also observed for specific proteins associated with the vascular system’s integrity. Although still subjected to the sensitivity of the algorithms and biomarkers employed, our results might contribute to the development of preventive therapeutic interventions

Translational genetic modelling of 3D craniofacial dysmorphology: elaborating the facial phenotype of neurodevelopmental disorders through the prism of schizophrenia

Purpose of Review: In the context of human developmental conditions, we review the conceptualisation of schizophrenia as a neurodevelopmental disorder, the status of craniofacial dysmorphology as a clinically accessible index of brain dysmorphogenesis, the ability of genetically modified mouse models of craniofacial dysmorphology to inform on the underlying dysmorphogenic process and how geometric morphometric techniques in mutant mice can extend quantitative analysis. Recent Findings: Mutant mice with disruption of neuregulin-1, a gene associated meta-analytically with risk for schizophrenia, constitute proof-of-concept studies of murine facial dysmorphology in a manner analogous to clinical studies in schizophrenia. Geometric morphometric techniques informed on the topography of facial dysmorphology and identified asymmetry therein. Summary: Targeted disruption in mice of genes involved in individual components of developmental processes and analysis of resultant facial dysmorphology using geometric morphometrics can inform on mechanisms of dysmorphogenesis at levels of incisiveness not possible in human subjects

Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimer's Disease

Model-based investigations of transneuronal spreading mechanisms in neurodegenerative diseases relate the pattern of pathology severity to the brain’s connectivity matrix, which reveals information about how pathology propagates through the connectivity network. Such network models typically use networks based on functional or structural connectivity in young and healthy individuals, and only end-stage patterns of pathology, thereby ignoring/excluding the effects of normal aging and disease progression. Here, we examine the sequence of changes in the elderly brain’s anatomical connectivity over the course of a neurodegenerative disease. We do this in a data-driven manner that is not dependent upon clinical disease stage, by using event-based disease progression modeling. Using data from the Alzheimer’s Disease Neuroimaging Initiative dataset, we sequence the progressive decline of anatomical connectivity, as quantified by graph-theory metrics, in the Alzheimer’s disease brain. Ours is the first single model to contribute to understanding all three of the nature, the location, and the sequence of changes to anatomical connectivity in the human brain due to Alzheimer’s disease. Our experimental results reveal new insights into Alzheimer’s disease: that degeneration of anatomical connectivity in the brain may be a viable, even early, biomarker and should be considered when studying such neurodegenerative diseases

Characterising Peritumoural Progression of Glioblastoma using Multimodal MRI

Glioblastoma is a highly malignant tumor which mostly recurs locally around the resected contrast enhancement. However, it is difficult to identify tumor invasiveness pre-surgically, especially in non-enhancing areas. Thus, the aim of this thesis was to utilize multimodal MR technique to identify and characterize the peritumoral progression zone that eventually leads to tumor progression. Patients with newly diagnosed cerebral glioblastoma were included consecutively from our cohort between 2010 and2014. The presurgical MRI sequences included volumetric T1-weighted with contrast, FLAIR, T2-weighted, diffusion-weighted imaging, diffusion tensor and perfusion MR imaging. Postsurgical and follow-up MRI included structural and ADC images. Image deformation, caused by disease nature and surgical procedure, renders routine coregistration methods inadequate for MRIs comparison between different time points. Therefore, a two-staged non-linear semi-automatic coregistration method was developed from the modification of the linear FLIRT and non-linear FNIRT functions in FMRIB’s Software Library (FSL). Utilising the above mentioned coregistration method, a volumetric study was conducted to analyse the extent of resection based on different MR techniques, including T1 weighted with contrast, FLAIR and DTI measures of isotropy (DTI-p) and anisotropy (DTI-q). The results showed that patients can have a better clinical outcome with a larger resection of the abnormal DTI q areas. Further study of the imaging characteristics of abnormal peritumoural DTI-q areas, using MRS and DCS-MRI, showed a higher Choline/NAA ratio (p = 0.035), especially higher Choline (p = 0.022), in these areas when compared to normal DTI-q areas. This was indicative of tumour activity in the peritumoural abnormal DTI-q areas. The peritumoural progression areas were found to have distinct imaging characteristics. In these progression areas, compared to non-progression areas within a 10 mm border around the contrast enhancing lesion, there was higher signal intensity in FLAIR (p = 0.02), and T1C (p < 0.001), and there were lower intensity in ADC (p = 0.029) and DTI-p (p < 0.001). Further applying radiomics features showed that 35 first order features and 77 second order features were significantly different between progression and non-progression areas. By using supervised convolutional neural network, there was an overall accuracy of 92.4% in the training set (n = 37) and 78.5% in the validation set (n=14). In summary, multimodal MR imaging, particularly diffusion tensor imaging, can demonstrate distinct characteristics in areas of potential progression on preoperative MRI, which can be considered potential targets for treatment. Further application of radiomics and machine learning can be potentially useful when identifying the tumor invasive margin before the surgery.Chung Gung Medical Foundatio

Imaging plus X: multimodal models of neurodegenerative disease

PURPOSE OF REVIEW: This article argues that the time is approaching for data-driven disease modelling to take centre stage in the study and management of neurodegenerative disease. The snowstorm of data now available to the clinician defies qualitative evaluation; the heterogeneity of data types complicates integration through traditional statistical methods; and the large datasets becoming available remain far from the big-data sizes necessary for fully data-driven machine-learning approaches. The recent emergence of data-driven disease progression models provides a balance between imposed knowledge of disease features and patterns learned from data. The resulting models are both predictive of disease progression in individual patients and informative in terms of revealing underlying biological patterns. RECENT FINDINGS: Largely inspired by observational models, data-driven disease progression models have emerged in the last few years as a feasible means for understanding the development of neurodegenerative diseases. These models have revealed insights into frontotemporal dementia, Huntington's disease, multiple sclerosis, Parkinson's disease and other conditions. For example, event-based models have revealed finer graded understanding of progression patterns; self-modelling regression and differential equation models have provided data-driven biomarker trajectories; spatiotemporal models have shown that brain shape changes, for example of the hippocampus, can occur before detectable neurodegeneration; and network models have provided some support for prion-like mechanistic hypotheses of disease propagation. The most mature results are in sporadic Alzheimer's disease, in large part because of the availability of the Alzheimer's disease neuroimaging initiative dataset. Results generally support the prevailing amyloid-led hypothetical model of Alzheimer's disease, while revealing finer detail and insight into disease progression. SUMMARY: The emerging field of disease progression modelling provides a natural mechanism to integrate different kinds of information, for example from imaging, serum and cerebrospinal fluid markers and cognitive tests, to obtain new insights into progressive diseases. Such insights include fine-grained longitudinal patterns of neurodegeneration, from early stages, and the heterogeneity of these trajectories over the population. More pragmatically, such models enable finer precision in patient staging and stratification, prediction of progression rates and earlier and better identification of at-risk individuals. We argue that this will make disease progression modelling invaluable for recruitment and end-points in future clinical trials, potentially ameliorating the high failure rate in trials of, e.g., Alzheimer's disease therapies. We review the state of the art in these techniques and discuss the future steps required to translate the ideas to front-line application.This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0